Advances in Multiple Sclerosis Research-Series I

Vasso Apostolopoulos, John Matsoukas, Vasso Apostolopoulos, John Matsoukas

Abstract

Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular, multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue, "Advances in Multiple Sclerosis Research-Series I", focused on delivery methods used for immunotherapeutic approaches, drug design, anti-inflammatories, identification of markers, methods for detection and monitoring MS and treatment modalities. The issue gained much attention with 20 publications, and, as a result, we launched Series II with the deadline for submission being 30 April 2021.

Keywords: MS; MS drugs; carriers; immunomodulation; multiple sclerosis; vaccine.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of new advances in Multiple Sclerosis Research—Series I, papers in the Special Issue. Created with biorender.com.

References

    1. Dargahi N., Katsara M., Tselios T., Androutsou M.E., de Courten M., Matsoukas J., Apostolopoulos V. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017;7:78. doi: 10.3390/brainsci7070078.
    1. Katsara M., Apostolopoulos V. Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Med. Chem. 2018;14:104–105. doi: 10.2174/157340641402180206092504.
    1. Katsara M., Matsoukas J., Deraos G., Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim. Biophys. Sin. 2008;40:636–642. doi: 10.1111/j.1745-7270.2008.00444.x.
    1. Basile M.S., Mazzon E., Mangano K., Pennisi M., Petralia M.C., Lombardo S.D., Nicoletti F., Fagone P., Cavalli E. Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis. Brain Sci. 2020;10:52. doi: 10.3390/brainsci10010052.
    1. Nemazannikova N., Mikkelsen K., Stojanovska L., Blatch G.L., Apostolopoulos V. Is there a Link between Vitamin B and Multiple Sclerosis? Med. Chem. 2018;14:170–180. doi: 10.2174/1573406413666170906123857.
    1. Virtanen J.O., Jacobson S. Viruses and multiple sclerosis. CNS Neurol. Disord. Drug Targets. 2012;11:528–544. doi: 10.2174/187152712801661220.
    1. Anagnostouli M., Artemiadis A., Gontika M., Skarlis C., Markoglou N., Katsavos S., Kilindireas K., Doxiadis I., Stefanis L. HLA-DPB1*03 as Risk Allele and HLA-DPB1*04 as Protective Allele for Both Early- and Adult-Onset Multiple Sclerosis in a Hellenic Cohort. Brain Sci. 2020;10:374. doi: 10.3390/brainsci10060374.
    1. Koukoulitsa C., Chontzopoulou E., Kiriakidi S., Tzakos A.G., Mavromoustakos T. A Journey to the Conformational Analysis of T-Cell Epitope Peptides Involved in Multiple Sclerosis. Brain Sci. 2020;10:356. doi: 10.3390/brainsci10060356.
    1. Nuti F., Fernandez F.R., Sabatino G., Peroni E., Mulinacci B., Paolini I., Pisa M.D., Tiberi C., Lolli F., Petruzzo M., et al. A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. Brain Sci. 2020;10:453. doi: 10.3390/brainsci10070453.
    1. Gudowska-Sawczuk M., Tarasiuk J., Kulakowska A., Kochanowicz J., Mroczko B. Kappa Free Light Chains and IgG Combined in a Novel Algorithm for the Detection of Multiple Sclerosis. Brain Sci. 2020;10:324. doi: 10.3390/brainsci10060324.
    1. Pitteri M., Ziccardi S., Dapor C., Guandalini M., Calabrese M. Lost in Classification: Lower Cognitive Functioning in Apparently Cognitive Normal Newly Diagnosed RRMS Patients. Brain Sci. 2019;9:321. doi: 10.3390/brainsci9110321.
    1. Buscarinu M.C., Fornasiero A., Pellicciari G., Renie R., Landi A.C., Bozzao A., Cappelletti C., Bernasconi P., Ristori G., Salvetti M. Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment. Brain Sci. 2019;9:299. doi: 10.3390/brainsci9110299.
    1. Sachinvala N.D., Stergiou A., Haines D.E., Kocharian A., Lawton A. Post-Craniopharyngioma and Cranial Nerve-VI Palsy Update on a MS Patient with Major Depression and Concurrent Neuroimmune Conditions. Brain Sci. 2019;9:281. doi: 10.3390/brainsci9100281.
    1. Kammona O., Kiparissides C. Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis. Brain Sci. 2020;10:333. doi: 10.3390/brainsci10060333.
    1. Metaxakis A., Petratou D., Tavernarakis N. Molecular Interventions towards Multiple Sclerosis Treatment. Brain Sci. 2020;10:299. doi: 10.3390/brainsci10050299.
    1. Apostolopoulos V., Rostami A., Matsoukas J. The Long Road of Immunotherapeutics against Multiple Sclerosis. Brain Sci. 2020;10:288. doi: 10.3390/brainsci10050288.
    1. Katsara M., Deraos G., Tselios T., Matsoukas J., Apostolopoulos V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J. Med. Chem. 2008;51:3971–3978. doi: 10.1021/jm8000554.
    1. Katsara M., Deraos G., Tselios T., Matsoukas M.T., Friligou I., Matsoukas J., Apostolopoulos V. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: Implications in the immunotherapy of multiple sclerosis. J. Med. Chem. 2009;52:214–218. doi: 10.1021/jm801250v.
    1. Katsara M., Deraos S., Tselios T.V., Pietersz G., Matsoukas J., Apostolopoulos V. Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL/J mice: Peptides in their free state versus mannan conjugation. Immunotherapy. 2014;6:709–724. doi: 10.2217/imt.14.42.
    1. Katsara M., Yuriev E., Ramsland P.A., Deraos G., Tselios T., Matsoukas J., Apostolopoulos V. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J. Neuroimmunol. 2008;200:77–89. doi: 10.1016/j.jneuroim.2008.06.013.
    1. Katsara M., Yuriev E., Ramsland P.A., Deraos G., Tselios T., Matsoukas J., Apostolopoulos V. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2. Mol. Immunol. 2008;45:3661–3670. doi: 10.1016/j.molimm.2008.04.024.
    1. Katsara M., Yuriev E., Ramsland P.A., Tselios T., Deraos G., Lourbopoulos A., Grigoriadis N., Matsoukas J., Apostolopoulos V. Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice. Immunology. 2009;128:521–533. doi: 10.1111/j.1365-2567.2009.03137.x.
    1. Lourbopoulos A., Deraos G., Matsoukas M.T., Touloumi O., Giannakopoulou A., Kalbacher H., Grigoriadis N., Apostolopoulos V., Matsoukas J. Cyclic MOG35-55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorg. Med. Chem. 2017;25:4163–4174. doi: 10.1016/j.bmc.2017.06.005.
    1. Lourbopoulos A., Matsoukas M.T., Katsara M., Deraos G., Giannakopoulou A., Lagoudaki R., Grigoriadis N., Matsoukas J., Apostolopoulos V. Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorg. Med. Chem. 2018;26:2221–2228. doi: 10.1016/j.bmc.2017.12.024.
    1. Deskoulidis E., Petrouli S., Apostolopoulos V., Matsoukas J., Topoglidis E. The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates. Brain Sci. 2020;10:577. doi: 10.3390/brainsci10090577.
    1. Chountoulesi M., Demetzos C. Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sci. 2020;10:338. doi: 10.3390/brainsci10060338.
    1. Thome R., Boehm A., Ishikawa L.L.W., Casella G., Munhoz J., Ciric B., Zhang G.X., Rostami A. Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation. Brain Sci. 2020;10:348. doi: 10.3390/brainsci10060348.
    1. Boziki M.K., Kesidou E., Theotokis P., Mentis A.A., Karafoulidou E., Melnikov M., Sviridova A., Rogovski V., Boyko A., Grigoriadis N. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020;10:234. doi: 10.3390/brainsci10040234.
    1. Dargahi N., Johnson J., Apostolopoulos V. Streptococcus thermophilus alters the expression of genes associated with innate and adaptive immunity in human peripheral blood mononuclear cells. PLoS ONE. 2020;15:e0228531. doi: 10.1371/journal.pone.0228531.
    1. Dargahi N., Johnson J., Donkor O., Vasiljevic T., Apostolopoulos V. Immunomodulatory effects of probiotics: Can they be used to treat allergies and autoimmune diseases? Maturitas. 2019;119:25–38. doi: 10.1016/j.maturitas.2018.11.002.
    1. Dargahi N., Matsoukas J., Apostolopoulos V. Streptococcus thermophilus ST285 Alters Pro-Inflammatory to Anti-Inflammatory Cytokine Secretion against Multiple Sclerosis Peptide in Mice. Brain Sci. 2020;10:126. doi: 10.3390/brainsci10020126.
    1. Moser T., Harutyunyan G., Karamyan A., Otto F., Bacher C., Chroust V., Leitinger M., Novak H.F., Trinka E., Sellner J. Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: A Comparative Study of Indication, Efficacy and Safety. Brain Sci. 2019;9:267. doi: 10.3390/brainsci9100267.
    1. Moccia M., Capacchione A., Lanzillo R., Carbone F., Micillo T., Matarese G., Palladino R., Brescia Morra V. Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-beta1a and Coenzyme Q10. Brain Sci. 2019;9:259. doi: 10.3390/brainsci9100259.
    1. Workman C.D., Ponto L.L.B., Kamholz J., Rudroff T. No Immediate Effects of Transcranial Direct Current Stimulation at Various Intensities on Cerebral Blood Flow in People with Multiple Sclerosis. Brain Sci. 2020;10:82. doi: 10.3390/brainsci10020082.
    1. Ahdab R., Shatila M.M., Shatila A.R., Khazen G., Freiha J., Salem M., Makhoul K., El Nawar R., El Nemr S., Ayache S.S., et al. Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment. Brain Sci. 2019;9:357. doi: 10.3390/brainsci9120357.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe